13F Holdings
中文EN

CLDI Calidi Biotherapeutics, Inc.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1855485 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY19.9%
TTM EPS YoY192.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-373.6%
ROA-163.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets70.5%
Debt / equity0.41x
Current ratio1.27x
Interest coverage-252.18x

Cash quality & payout

Operating cash flow / net income0.99x
Accruals ratio-1.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue———$45,000
R&D expense$9.74M$8.88M$13.01M$7.26M
SG&A expense$10.50M$12.90M$15.98M$15.90M
Operating income-$20.24M-$21.78M-$28.99M-$23.13M
Interest expense$100,000$700,000$1.10M$200,000
Pretax income-$20.05M-$22.20M-$29.20M-$25.42M
Income tax$15,000$14,000$16,000$11,000
Net income-$19.91M-$22.14M-$29.22M-$25.43M
EBITDA-$18.59M-$20.24M-$28.60M-$22.87M
EPS (basic)-5.95-35.70-17.332.99
EPS (diluted)-5.95-35.70-17.332.99
Weighted avg. shares (diluted)4,3026671.69M8.51M
Balance sheet
Cash & equivalents$5.82M$9.81M$2.17M$590,000
Receivables———$870
Current assets$6.26M$10.23M$4.30M$786,000
PP&E, net$781,000$869,000$1.27M$1.27M
Total assets$8.86M$14.18M$10.02M$2.60M
Current liabilities$3.94M$9.50M$10.23M$42.99M
Short-term debt$90,000$3.22M$807,000$5.42M
Long-term debt$600,000$600,000$2.06M—
Total debt$690,000$3.82M$2.87M—
Total liabilities$5.10M$12.21M$18.25M$43.44M
Shareholders' equity$3.76M$1.53M-$8.23M-$50.44M
Net debt-$5.13M-$5.99M$700,000—
Shares outstanding451,0761.73M3.55M8.58M
Cash flow statement
Operating cash flow-$21.29M-$19.69M-$26.98M-$13.21M
Investing cash flow-$170,000-$16,000-$478,000-$494,000
Financing cash flow$17.46M$27.36M$29.04M$12.09M
Depreciation & amortization$1.65M$1.53M$392,000$260,000
Stock-based compensation$2.11M$2.96M$4.81M$4.52M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.